133 related articles for article (PubMed ID: 38355016)
21. Pemetrexed and gemcitabine as combination therapy for the treatment of Group3 medulloblastoma.
Morfouace M; Shelat A; Jacus M; Freeman BB; Turner D; Robinson S; Zindy F; Wang YD; Finkelstein D; Ayrault O; Bihannic L; Puget S; Li XN; Olson JM; Robinson GW; Guy RK; Stewart CF; Gajjar A; Roussel MF
Cancer Cell; 2014 Apr; 25(4):516-29. PubMed ID: 24684846
[TBL] [Abstract][Full Text] [Related]
22. Novel Molecular Hallmarks of Group 3 Medulloblastoma by Single-Cell Transcriptomics.
Qin C; Pan Y; Li Y; Li Y; Long W; Liu Q
Front Oncol; 2021; 11():622430. PubMed ID: 33816256
[TBL] [Abstract][Full Text] [Related]
23. Medulloblastoma drugs in development: Current leads, trials and drawbacks.
Wen J; Hadden MK
Eur J Med Chem; 2021 Apr; 215():113268. PubMed ID: 33636537
[TBL] [Abstract][Full Text] [Related]
24. Molecular and functional profiling of chemotolerant cells unveils nucleoside metabolism-dependent vulnerabilities in medulloblastoma.
Mariotto E; Rampazzo E; Bortolozzi R; Rruga F; Zeni I; Manfreda L; Marchioro C; Canton M; Cani A; Magni R; Luchini A; Bresolin S; Viola G; Persano L
Acta Neuropathol Commun; 2023 Nov; 11(1):183. PubMed ID: 37978570
[TBL] [Abstract][Full Text] [Related]
25. Combination drug screen identifies synergistic drug interaction of BCL-XL and class I histone deacetylase inhibitors in MYC-amplified medulloblastoma cells.
Zeuner S; Vollmer J; Sigaud R; Oppermann S; Peterziel H; ElHarouni D; Oehme I; Witt O; Milde T; Ecker J
J Neurooncol; 2024 Jan; 166(1):99-112. PubMed ID: 38184819
[TBL] [Abstract][Full Text] [Related]
26. The rationale for targeted therapies in medulloblastoma.
MacDonald TJ; Aguilera D; Castellino RC
Neuro Oncol; 2014 Jan; 16(1):9-20. PubMed ID: 24305711
[TBL] [Abstract][Full Text] [Related]
27. BMI1 is a therapeutic target in recurrent medulloblastoma.
Bakhshinyan D; Venugopal C; Adile AA; Garg N; Manoranjan B; Hallett R; Wang X; Mahendram S; Vora P; Vijayakumar T; Subapanditha M; Singh M; Kameda-Smith MM; Qazi M; McFarlane N; Mann A; Ajani OA; Yarascavitch B; Ramaswamy V; Farooq H; Morrissy S; Cao L; Sydorenko N; Baiazitov R; Du W; Sheedy J; Weetall M; Moon YC; Lee CS; Kwiecien JM; Delaney KH; Doble B; Cho YJ; Mitra S; Kaplan D; Taylor MD; Davis TW; Singh SK
Oncogene; 2019 Mar; 38(10):1702-1716. PubMed ID: 30348991
[TBL] [Abstract][Full Text] [Related]
28. Pediatric medulloblastoma in the molecular era: what are the surgical implications?
Kameda-Smith MM
Cancer Metastasis Rev; 2020 Mar; 39(1):235-243. PubMed ID: 32095940
[TBL] [Abstract][Full Text] [Related]
29. Combined functional genomic and chemical screens identify SETD8 as a therapeutic target in MYC-driven medulloblastoma.
Veo B; Danis E; Pierce A; Sola I; Wang D; Foreman NK; Jin J; Ma A; Serkova N; Venkataraman S; Vibhakar R
JCI Insight; 2019 Jan; 4(1):. PubMed ID: 30626740
[TBL] [Abstract][Full Text] [Related]
30. Pediatric brain tumors: Update of proteome-based studies.
Tsangaris GT; Anagnostopoulos AK
J Proteomics; 2018 Sep; 188():41-45. PubMed ID: 29471057
[TBL] [Abstract][Full Text] [Related]
31. Histone chaperone FACT complex inhibitor CBL0137 interferes with DNA damage repair and enhances sensitivity of medulloblastoma to chemotherapy and radiation.
Song H; Xi S; Chen Y; Pramanik S; Zeng J; Roychoudhury S; Harris H; Akbar A; Elhag SS; Coulter DW; Ray S; Bhakat KK
Cancer Lett; 2021 Nov; 520():201-212. PubMed ID: 34271103
[TBL] [Abstract][Full Text] [Related]
32. Oncolytic effects of parvovirus H-1 in medulloblastoma are associated with repression of master regulators of early neurogenesis.
Lacroix J; Schlund F; Leuchs B; Adolph K; Sturm D; Bender S; Hielscher T; Pfister SM; Witt O; Rommelaere J; Schlehofer JR; Witt H
Int J Cancer; 2014 Feb; 134(3):703-16. PubMed ID: 23852775
[TBL] [Abstract][Full Text] [Related]
33. Synergistic activity of BET inhibitor MK-8628 and PLK inhibitor Volasertib in preclinical models of medulloblastoma.
Han Y; Lindner S; Bei Y; Garcia HD; Timme N; Althoff K; Odersky A; Schramm A; Lissat A; Künkele A; Deubzer HE; Eggert A; Schulte JH; Henssen AG
Cancer Lett; 2019 Mar; 445():24-33. PubMed ID: 30611741
[TBL] [Abstract][Full Text] [Related]
34. The LIN28B-let-7-PBK pathway is essential for group 3 medulloblastoma tumor growth and survival.
Shahab SW; Roggeveen CM; Sun J; Kunhiraman H; McSwain LF; Juraschka K; Kumar SA; Saulnier O; Taylor MD; Schniederjan M; Schnepp RW; MacDonald TJ; Kenney AM
Mol Oncol; 2023 Sep; 17(9):1784-1802. PubMed ID: 37341142
[TBL] [Abstract][Full Text] [Related]
35. Blockade of Inhibitors of Apoptosis Proteins in Combination with Conventional Chemotherapy Leads to Synergistic Antitumor Activity in Medulloblastoma and Cancer Stem-Like Cells.
Chen SM; Li YY; Tu CH; Salazar N; Tseng YY; Huang SF; Hsieh LL; Lui TN
PLoS One; 2016; 11(8):e0161299. PubMed ID: 27537345
[TBL] [Abstract][Full Text] [Related]
36. Urinary protein biomarkers for pediatric medulloblastoma.
Hao X; Guo Z; Sun H; Liu X; Zhang Y; Zhang L; Sun W; Tian Y
J Proteomics; 2020 Aug; 225():103832. PubMed ID: 32474013
[TBL] [Abstract][Full Text] [Related]
37. Metabolism-based targeting of MYC via MPC-SOD2 axis-mediated oxidation promotes cellular differentiation in group 3 medulloblastoma.
Martell E; Kuzmychova H; Kaul E; Senthil H; Chowdhury SR; Morrison LC; Fresnoza A; Zagozewski J; Venugopal C; Anderson CM; Singh SK; Banerji V; Werbowetski-Ogilvie TE; Sharif T
Nat Commun; 2023 May; 14(1):2502. PubMed ID: 37130865
[TBL] [Abstract][Full Text] [Related]
38. Childhood Medulloblastoma: An Overview.
Suk Y; Gwynne WD; Burns I; Venugopal C; Singh SK
Methods Mol Biol; 2022; 2423():1-12. PubMed ID: 34978683
[TBL] [Abstract][Full Text] [Related]
39. Targeting Angiogenic Factors for the Treatment of Medulloblastoma.
Saker Z; Rizk M; Bahmad HF; Nabha SM
Curr Treat Options Oncol; 2022 Jun; 23(6):864-886. PubMed ID: 35412196
[TBL] [Abstract][Full Text] [Related]
40. Tacedinaline (CI-994), a class I HDAC inhibitor, targets intrinsic tumor growth and leptomeningeal dissemination in MYC-driven medulloblastoma while making them susceptible to anti-CD47-induced macrophage phagocytosis via NF-kB-TGM2 driven tumor inflammation.
Marquardt V; Theruvath J; Pauck D; Picard D; Qin N; Blümel L; Maue M; Bartl J; Ahmadov U; Langini M; Meyer FD; Cole A; Cruz-Cruz J; Graef CM; Wölfl M; Milde T; Witt O; Erdreich-Epstein A; Leprivier G; Kahlert U; Stefanski A; Stühler K; Keir ST; Bigner DD; Hauer J; Beez T; Knobbe-Thomsen CB; Fischer U; Felsberg J; Hansen FK; Vibhakar R; Venkatraman S; Cheshier SH; Reifenberger G; Borkhardt A; Kurz T; Remke M; Mitra S
J Immunother Cancer; 2023 Jan; 11(1):. PubMed ID: 36639156
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
